---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-025289"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-06-26T23:59:59+00:00"
generated_at: "2026-06-01T01:33:39.534063+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Evofem amends Series F-1 Preferred; conversion price set at $0.0154, adjustment provisions removed

## Summary
- Amended Certificate of Designation removes Section 8(h) adjustment provisions from Series F-1 Preferred.
- Conversion Price changed to $0.0154 per share; previously subject to adjustment.
- Approved by unanimous written consent of Required Holders.
- Filed with Delaware Secretary of State on June 20, 2024.

## SEC filing metadata
- accession: 0001493152-24-025289
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.03, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224025289/0001493152-24-025289-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224025289/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-025289
- JSON: https://secwatch.observer/filing/0001493152-24-025289.json
- Plain text: https://secwatch.observer/filing/0001493152-24-025289.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.